Navigation Links
Genomic Health Announces First Quarter 2011 Financial Results and Business Progress
Date:5/3/2011

r the same period in 2010 of $4.3 million.

Cash and cash equivalents and investments in marketable securities at March 31, 2011 were $76.6 million compared with $76.8 million at December 31, 2010.

In the first quarter of 2011, more than 16,230 Oncotype DX test results were delivered, an increase of 22 percent compared with more than 13,310 test results delivered in the first quarter of 2010.

The company maintains financial guidance for the full-year ending December 31, 2011:

  • Total revenue of $200 to $210 million
  • Full-year net income of $3 to $5 million
  • Oncotype DX test results delivered of 63,000 to 66,000

  • Quarterly HighlightsOncotype DX Breast Cancer Commercial Progress

  • Secured reimbursement for estrogen-receptor positive breast cancer patients with one to three positive nodes with Excellus, a payor covering 1.8 million lives in New York. 
  • Increased covered lives outside of the United States to more than 42 million through reimbursement arrangements now including payors and institutions in Canada, Germany, Greece, Ireland, Israel, Mexico, Spain, Venezuela and the United Kingdom.
  • AOK Rheinland/Hamburg, a national health insurance provider in Germany, announced it will reimburse Oncotype DX as part of a treatment study being conducted by the West German Study Group.
  • Initiated a decision impact study of Oncotype DX in Australia.
  • Launched a Spanish language version of the Oncotype DX breast cancer website.
  • Established a distribution agreement to provide the Oncotype DX breast and colon cancer tests in South Africa, Botswana, Namibia, and Kenya.

  • Oncotype DX Colon Cancer Commercial Progress

  • Partnered with the advocacy organization, Fight Colore
    '/>"/>

  • SOURCE Genomic Health, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting
    2. Transgenomic Announces Discovery of a Novel Technique Which Enhances Analytic Sensitivity of Standard Sanger Sequencing to 1%
    3. Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test
    4. Reminder Webcast Alert: Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
    5. Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
    6. Everist Genomics Laboratory Receives Approval From U.S. Regulatory Authorities For High Complexity Clinical Testing
    7. Researchers use genomics to investigate TB outbreak
    8. Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17
    9. Genomic Health Announces Results from Biomarker Discovery Program Utilizing Next-Generation Sequencing to Compare Normal and Tumor Breast Tissue
    10. Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database
    11. Four Community Hospitals Join DNA Directs Genomic Medicine Network
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/21/2014)... 20, 2014 Polaris Group announced today ... its Phase 1 trial of ADI-PEG 20 in ... of malignant pleural mesothelioma (MPM) and non-squamous non-small ... trials on ADI-PEG 20, both as monotherapy and ... of several other indications, including breast cancer, melanomas, ...
    (Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014  Cytori Therapeutics ... Marc Hedrick , M.D. will present live at VirtualInvestorConferences.com ... 4, 2014 TIME:    11:15 am PT / 2:15 ... this URL into your browser,s address bar: http://bit.ly/1B2KGaL ... time and receive event updates. This will ...
    (Date:11/18/2014)... SAN BRUNO, Calif. , Nov. 18, 2014 ... is a platinum sponsor of the 10th Annual World Stem ... and regenerative medicine stakeholders. The 2014 World Stem Cell Summit ... San Antonio, Texas . ... the discovery and development of lifesaving cures and therapies, convening ...
    (Date:11/18/2014)... 17, 2014 Cirrascale Corporation ... blade-based and rackmount computing infrastructure, today announced it ... accelerator throughout its GPU-enabled blade server and high-performance ... company’s latest proprietary 80-lane Gen3 PCIe switch-enabled risers, ... Tesla K80 dual-GPU accelerator cards in a single ...
    Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3
    ... 12 Odyssey Thera, Inc.,announced today that the ... No. 7,306,914, entitled "Protein-fragment Complementation,Assays (PCA) in whole ... infectious disease and gene therapy." This is the,twelfth ... The patent describes a method for detecting protein-protein,interactions ...
    ... "Rolling" NDA for Intravenous Iclaprim in cSSSI; Electronic Submission of ... First Modules due Before ... ARPN) announced today the enrolment and dosing of the first ... the treatment,of hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia,(VAP) / healthcare-associated ...
    ... (Nasdaq:,INSM), today announced that it has been awarded ... (MDA). The grant is expected to cover a,substantial ... 24-week,Phase 3 enabling trial in patients with Myotonic ... biopharmaceutical company with extensive,expertise in biologics and orphan ...
    Cached Biology Technology:Odyssey Thera Granted U.S. Patent for Animal Imaging 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 3First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 4First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 5Insmed Awarded $2.1 Million by Muscular Dystrophy Association 2Insmed Awarded $2.1 Million by Muscular Dystrophy Association 3
    (Date:11/4/2014)... amount of death at the right time might actually ... research that could help in understanding animal populations, pest ... a paper in the journal Trends in Ecology ... colleagues conclude that the kind of positive population effect ... or mortality, depends on the size and developmental stage ...
    (Date:11/4/2014)... Think about the way our bodies are assembled during ... that they are supposed to become a nerve or ... the correct place and alignment? Researchers at the University ... In a new study, UM researchers describe the signaling ... neighbors, at the head-trunk region. Their discovery may have ...
    (Date:11/4/2014)...   3D scanner developer targets ... Fuel3D , a developer of 3D scanning solutions, today announced ... (£4 million). This funding builds on the company,s initial $2.6 ... the way for the commercial launch of the company,s consumer ... led by Chimera Partners and will be used to ramp-up ...
    Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2The inside story: How the brain and skull stay together 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
    ... lobe dementia ,Frontal lobe dementia (Frontotemporal Dementia, FTD) ... is the form of dementia that occurs most frequently in ... in the frontal lobe where large numbers of brain cells ... part of the brain and constitutes about 30% of the ...
    ... J. Craig Venter, Energy Bioscience Institute,s Chris Somerville ... Department of Energy Joint Genome Institute (DOE JGI) ... March 25-27, 2009 in Walnut Creek, Calif. ... of renewable energy strategies, biomass conversion to biofuels, ...
    ... GAINESVILLE, Fla. Older, active people who have a drink ... according to a report today from a University of Florida ... and Drugs . Although people 50 or older in ... they performed worse on special tests after having moderate amounts ...
    Cached Biology News:Blood test predicts chance of dementia 2Venter, Somerville and Church highlight DOE/JGI genomics of energy and environment meeting 2After a few drinks, older adults more impaired than they think 2After a few drinks, older adults more impaired than they think 3
    ... 48° Fixed Angle Polypropylene Rotor ... Series, IEC Centra CL3/CL3R** and Centra-MP4/MP4R*. ... quiet operation. /MP4, ,EXCLUSIVE polypropylene rotor ... can be repeatedly autoclaved. Polypropylene ...
    The 891 45° Fixed Angle Rotor is designed to provide aerosol containment and can be removed from a centrifuge (seal entact) and opened under an environmental hood....
    ... The Xcise is a powerful technology ... throughput proteome analysis. High quality sample ... untrained user. , The Xcise is a ... for high throughput proteome analysis. It combines ...
    Extra Large bottle for hybridization 300 x 70mm...
    Biology Products: